EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pharmaceutical policy and innovation for rare diseases: A narrative review

Adrián Alonso Ruiz iD, Kaitlin Large, Suerie Moon, Marcela Vieira iD

F1000Research · 2023

DOI: 10.12688/f1000research.130809.2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift F1000Research, 2023. Verfasst von Adrián Alonso Ruiz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Global Health Centre, Graduate Institute of International and Development Studies, Geneva, 1211, Switzerland. Hauptthemen laut MEDLINE: Rare Diseases, Orphan Drug Production. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This article aims to synthesize the existing literature on the implementation of public policies to incentivize the development of treatments for rare diseases, (diseases with very low prevalence and therefore with low commercial interest) otherwise known as orphan drugs. The implementation of these incentives in the United States (US), Japan, and in the European Union (EU) seems to be related to a substantial increase in treatments for these diseases, and has influenced the way the pharmaceutical research & development (R&D) system operates beyond this policy area. Despite the success of the Orphan Drug model, the academic literature also highlights the negative implications that these public policies have on affordability and access to orphan drugs, as well as on the prioritization of certain disease rare areas over others. The synthesis focuses mostly on the United States’ Orphan Drug Act (ODA) as a model for subsequent policies in other regions and countries. It starts with a historical overview of the creation of the term “rare diseases”, continues with a summary of the evidence available on the US ODA’s positive and negative impacts, and provides a summary of the different proposals to reform these incentives in light of the negative outcomes described. Finally, it describes some key aspects of the Japanese and European policies, as well as some of the challenges captured in the literature related to their impact in Low- and Middle-Income Countries (LMICs).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rare DiseasesOrphan Drug ProductionHumansUnited StatesEuropean UnionHealth PolicyJapan

Stichwörter der Autor:innen

access to medicineshealth policyinnovation policypharmaceutical innovationpharmaceutical policyrare diseases

Autor:innen und Institutionen

  • Global Health Centre, Graduate Institute of International and Development Studies, Geneva, 1211, Switzerland.

ORCID-Profile: Adrián Alonso Ruiz, Marcela Vieira

Förderung

  • Swiss National Science Foundation

Zitieren

APA

Alonso Ruiz, A., Large, K., Moon, S., & Vieira, M. (2023). Pharmaceutical policy and innovation for rare diseases: A narrative review. F1000Research. https://doi.org/10.12688/f1000research.130809.2

Vancouver

Alonso Ruiz A, Large K, Moon S, Vieira M. Pharmaceutical policy and innovation for rare diseases: A narrative review. F1000Research. 2023. doi:10.12688/f1000research.130809.2

BibTeX
@article{AlonsoRuiz2023,
  author = {Alonso Ruiz, Adrián and Large, Kaitlin and Moon, Suerie and Vieira, Marcela},
  title = {Pharmaceutical policy and innovation for rare diseases: A narrative review},
  journal = {F1000Research},
  year = {2023},
  doi = {10.12688/f1000research.130809.2}
}
Kostenlos starten →